Update on immunotherapy trials for AML from ASH 2017: bispecific DARTs, CAR T-cells and antibody-drug conjugates
Description: Immunotherapy for acute myeloid leukemia (AML) is an exciting area, with clinical trials, including those that are first-in-human, showing promising results. Here, Marina Konopleva, MD, PhD, from the University of Texas MD Anderson Cancer Center, Houston, TX, provides an update on a range of these trials, including response rates and toxicities. Dr Konopleva covers the trial of the bispecific CD3xCD123 DART, flotetuzumab (NCT02152956); a next-generation CD123-targeting CAR T-cell therapy (NCT02159495); and the antibody-drug conjugate IMG9N77, which targets CD33 (NCT02674763). This video was recorded at the American Society of Hematology (ASH) 2017 Annual Meeting and Exposition in Atlanta, GA.
Shared By : VJHemOnc
Posted on : 01/09/18
Added : 3 months ago